



**HAL**  
open science

## Using KASP technique to screen LRRK2 G2019S mutation in a large Tunisian cohort

Zied Landoulsi, Sawssan Benromdhan, Mouna Ben Djebara, Mariem Damak, Hamza Dallali, Rym Kefi, Sonia Abdelhak, Amina Gargouri-Berrechid, Chokri Mhiri, Riadh Gouider

► **To cite this version:**

Zied Landoulsi, Sawssan Benromdhan, Mouna Ben Djebara, Mariem Damak, Hamza Dallali, et al.. Using KASP technique to screen LRRK2 G2019S mutation in a large Tunisian cohort. *BMC Medical Genetics*, 2017, 18 (1), pp.70. 10.1186/s12881-017-0432-5 . pasteur-01639043

**HAL Id: pasteur-01639043**

**<https://riip.hal.science/pasteur-01639043>**

Submitted on 20 Nov 2017

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution 4.0 International License

RESEARCH ARTICLE

Open Access



# Using KASP technique to screen *LRRK2* G2019S mutation in a large Tunisian cohort

Zied Landoulsi<sup>1,2</sup>, Sawssan Benromdhan<sup>3</sup>, Mouna Ben Djebara<sup>1,4</sup>, Mariem Damak<sup>3</sup>, Hamza Dallali<sup>2,5</sup>, Rym Kefi<sup>2</sup>, Sonia Abdelhak<sup>2</sup>, Amina Gargouri-Berrechid<sup>1,4</sup>, Chokri Mhiri<sup>3</sup> and Riadh Gouider<sup>1,4\*</sup> 

## Abstract

**Background:** In North African populations, G2019S mutation in *LRRK2* gene, encoding for the leucine-rich repeat kinase 2, is the most prevalent mutation linked to familial and sporadic Parkinson's disease (PD). Early detection of G2019S by fast genetic testing is very important to guide PD's diagnosis and support patients and their family caregivers for better management of their life according to disease's evolution.

**Methods:** In our study, a genetic PD's diagnosis tool was developed for large scale genotyping using Kompetitive Allele Specific PCR (KASP) technology. We investigated *G2019S*'s frequency in 250 Tunisian PD patients and 218 controls.

**Results:** We found that 33.6% of patients and 1.3% of controls were carriers. Demographic characteristics of patients with G2019S had no differences compared with non-carrier patients. Thereby, we could emphasize the implication of G2019S in PD without any distinctive demographic factors in the studied cohort. Sixty patients out of 250 were genotyped using Taqman assay and Sanger sequencing. The genotyping results were found to be concordant with KASP assay.

**Conclusions:** The G2019S mutation frequency in our cohort was similar to that reported in previous studies. Comparing to Taqman assay and Sanger sequencing, KASP was shown to be a reliable, time and cost effective genotyping assay for routine G2019S screening in genetic testing laboratories.

**Keywords:** Parkinson's disease, *LRRK2* gene, G2019S, KASP, genetic testing

## Background

In the last decade, genetic research has made tremendous progress in identifying the genetic etiology of Parkinson's disease (PD). Mutations in *LRRK2* gene, encoding for the leucine-rich repeat kinase 2, were found to be the most frequent cause of late-onset autosomal dominant form of PD [1, 2]. The *LRRK2* gene, located on chromosome 12q12 with 51 exons, encodes a highly conserved 2527 amino-acid multi-domain protein having kinase and GTPase functions [3]. Among 80 missense variants in *LRRK2* gene, 7 mutations are associated with dominantly inherited forms of PD, and are clustered in functionally important regions [4]. The most prevalent *LRRK2* mutation is the c.6055 G > A in exon 41, which

causes a glycine to serine substitution (G2019S) in the highly conserved activation loop of its MAP kinase domain [5]. The G2019S was shown to have a worldwide distribution [6]. Globally, this mutation occurs in 3 to 6% of familial PD and in 1 to 2% of sporadic PD [7]. However, its frequency varied greatly according to geographical or ethnic origin with the highest values seen in North African (37% of familial PD and 41% of sporadic PD) and Ashkenazi Jews (30% of familial PD and 13% of sporadic PD). Lower frequencies of this mutation were observed in sporadic and familial PD patients in North American (3 and 1%), European (4 and 1%) and Asian populations (0.1 and 0%) [6].

Although it is rarely found in healthy controls, genetic testing for *LRRK2* mutations is very important to support PD patients and their families. Thus, a fast and accurate genotyping method should be taken into account to screen the G2019S mutation. Early genotyping

\* Correspondence: riadh.gouider@gnet.tn

<sup>1</sup>Department of Neurology, UR12SP21, Razi Hospital, 1 rue des Orangers, 2010 Tunis, Manouba, Tunisia

<sup>4</sup>Faculty of Medicine of Tunis, University of Tunis El Manar, Tunis, Tunisia  
Full list of author information is available at the end of the article

routine was commonly based on direct sequencing. This technique was then replaced by real-time polymerase chain reaction (PCR) based genotyping methods including TaqMan assay and high resolution melting technique. These methods are low-priced, less time-consuming and highly-sensitive. Recently, the Kompetitive Allele Specific PCR (KASP) genotyping assay has been successfully used to validate DNA polymorphisms. This uniplex, fluorescence-based genotyping technology, is based on allele-specific primer extension [8]. It offers the simplest and the most cost-effective way to determine precisely single-nucleotide polymorphism (SNP) genotypes.

In this work, we used KASP genotyping assay to screen the *LRRK2* G2019S mutation in a cohort of Tunisian PD patients. Through this technique, we aimed to develop a genetic diagnostic tool for large scale genotyping.

## Methods

### Patients and control subjects

A series of 250 Tunisian unrelated PD patients (96 familial and 154 apparently sporadic cases) were recruited at the Neurology Department, Razi Hospital (La Manouba, Tunisia). Patients were diagnosed as being affected if they satisfied the United Kingdom Parkinson's disease Society (UKPDS) brain bank criteria, except the exclusion of family history of PD. In addition to PD patients, 218 Tunisian unrelated control subjects were recruited from different primary care clinics. They did not have symptoms or family history of neurological disorders.

### KASP genotyping assay

Genomic DNA was extracted from peripheral blood of subjects using the Salting-out method [9]. The 468 DNA samples, including 250 PD patients and 218 controls, were genotyped using the KASP assay.

The KASP assay mix required to determine SNP genotypes was purchased from LGC Genomics (Beverly, MA) using 'KASP by Design' method. The SNP of interest (rs34637584) and a 500 base-pairs (bp) sequence surrounding the SNP were annotated with known variants using ENSEMBL genome browser and were submitted to LGC Genomics website via their SNP submission template. The designed KASP assay mix comprised three primers (two allele-specific and one common reverse primer).

DNA samples were dispatched in 96-well plates. Two DNA controls were included in each reaction plate. The DNA controls were samples from one normal individual and a second individual heterozygous for the G2019S mutation selected from Whole Exome Sequencing (WES) data collected from the database of the Laboratory of Biomedical Genomics and Oncogenetics. No

positive homozygous control was available. KASP reactions were done following the manufacturer's protocol (LGC Genomics, Beverly, MA) using 50 ng of DNA in a 5  $\mu$ l reaction volume. Reactions were carried-out in a 96-Well Light Cycler 480 II (Roche, CA) at the following conditions: 94 °C for 15 min, then 10 cycles of 94 °C for 20 s, 61 °C for 1 min, followed by 26 cycles of 94 °C for 20 s and 1 min at 55 °C. Following the PCR, fluorescence was detected using a single quantification cycle of 37 °C for 1 s after cooling at 37 °C for 1 min. Data were analyzed using the "Endpoint Genotyping" method of the Light Cycler 480 Software (release 1.5.0).

### TaqMan assay

Among the 250 PD patients, 60 were screened for *LRRK2* G2019S mutation by an allelic discrimination Taqman assay. According to the manufacturer's manual, the genotyping reaction was composed of TaqMan universal PCR master mix (Applied Biosystems Master Mix, catalogue number 4351379), TaqMan SNP genotyping reagent which included forward and reverse primers and SNP specific probe labeled with VIC dye conjugated to the 5' end of the wild type allele probes and FAM dye conjugated to the 5' end of the mutated allele probes. Allelic discrimination was automatically carried-out with PRISM 7000 sequence detection system (Applied Biosystems, CA).

### Sanger sequencing

Exon 41 of *LRRK2* gene was amplified by PCR from genomic DNA of 60 PD patients (already genotyped by Taqman and KASP assay) using two primers: 5'-TTTCCTGTGCATTTTCTGGCA-3' and 5'-TGAGA CAGACCTGATCACCTA-3' under the following reaction conditions: denaturation at 95 °C for 5 min followed by 30 cycles of 95 °C for 30 s, 60 °C for 30 s and 72 °C for 30 s; and a final cycle of 7-min extension at 72 °C. PCR products were purified and sequenced using the Big-dye terminator Cycle Sequencing Kit v1.1 on an 3500xL Genetic Analyzer DNA sequencer (Applied Biosystems, CA). Sequences were analyzed using the Seqscape software (Applied Biosystems, CA).

### Statistical analyses

Statistical analyses were conducted using GraphPad Prism software version 5.03. The rs34637584 genotypes were examined for deviation from Hardy-Weinberg equilibrium (HWE) using Chi-square test. Statistical comparison of PD patients and controls with and without the G2019S mutation was performed where appropriate using Fisher's exact test and F-test to compare variance.

## Results

Tunisian PD patients (250) and controls (218) were genotyped using the KASP assay. Our study revealed that the *LRRK2* G2019S mutation was present in 84 of 250 PD patients (33.6%) and in 3 of 218 controls (1.3%). Among the eighty-four G2019S carriers, 76 were heterozygous (30.4%) and 8 were homozygous (3.2%) for the mutation. No deviation from HWE was observed among PD patients ( $P > 0.05$ ). All control G2019S carriers (3 individuals) were heterozygous. The frequency of the mutation among patients with familial cases (96 patients) was 37.5% (36 patients, 30 heterozygous and 6 homozygous) and 31% (48 patients, 46 heterozygous and 2 homozygous) in sporadic cases (154 patients).

In order to assess the accuracy of the KASP assay, genotyping results of 60 DNA samples of PD patients were verified through TaqMan assay and Sanger sequencing. Genotyping results were identical to those obtained by KASP.

Demographic characteristics of PD patients and controls were shown in Table 1. Both groups have equivalent sex ratios and similar mean age and age of onset. Demographic data of patients were stratified according to *LRRK2* G2019S (Table 2). The means of age of onset and gender distribution were not significantly different between carriers (homozygous and heterozygous individuals) and non-carriers. Furthermore, it seemed that the presence of G2019S mutation did not have an effect on the clinical picture of the sporadic nor on the familial form of PD. The mean age of onset was relatively similar in carriers ( $56.4 \pm 13$  for sporadic vs  $55.8 \pm 12.4$  for familial,  $p = 0.76$ ) and non-carriers ( $61.8 \pm 10.8$  for sporadic vs  $55.8 \pm 12.9$  for familial,  $p = 0.12$ ).

## Discussion

In the present study, we reported a large series of Tunisian patients in which the high frequency of the G2019S mutation seemed to be the cause of autosomal dominant PD. The mutation frequency among patients (33.6% of total, 37.5% of familial cases and 31% for sporadic cases) was in agreement with previously reported series of PD patients from Tunisia and North Africa. Frequency studies

revealed a strikingly high value in North Africa (40.3% of familial and 33% of sporadic cases) [6]. Therefore, the G2019S mutation could be considered of clinical utility for the early molecular diagnosis and treatment of PD.

The mutation was also present in a 1.3% of control individuals. According to published reports, one of the highest frequencies of G2019S was found in North African controls (1.5%) [6]. Moreover, genetic screening in North African unrelated healthy subjects showed that the incidence of G2019S was 1.57% in 127 Tunisian controls [10]. However, the mean age of controls with G2019S mutation was lower than the general mean age at onset of PD. These individuals might be considered at risk carriers that could eventually develop PD within a decade or could probably be in the prodromal phase of PD.

Previous studies reported Tunisian families included in large cohorts of heterogeneous ethnic groups and G2019S frequencies were calculated for the whole North African population including Tunisia, Algeria and Morocco [7, 11, 12]. Specific data concerning the G2019S mutation in the Tunisian population were included only in three different reports summarized in Table 3. We noted that there was no overlap between our cohort and those described in previous studies. The first study reported a frequency of 42% in 91 Tunisian families [13] and a common ancestral founding haplotype was shared by these families and those from the United States, as well as from several European and Middle Eastern countries [14]. The second report was a case-control study performed on 238 patients with sporadic PD and 371 controls [15]. Later, clinical features of *LRRK2* G2019S parkinsonism were studied in a 570 unrelated and 288 related patients including 220 sporadic (38%) and 126 familial cases (45%) who were carriers of the mutation [16]. In the same report, the mutation was also detected in 12 of 580 unrelated controls (3%).

In our study, the age of onset was similar between *LRRK2* G2019S homozygous, heterozygous and non-carriers. Moreover, in these three groups, no significant differences of age of onset were shown when familial and sporadic forms were compared. These results were

**Table 1** Demographics of Patients and Control subjects

|                                  | ALL           |               |                 | LRRK2 G2019S carriers |            |
|----------------------------------|---------------|---------------|-----------------|-----------------------|------------|
|                                  | Patients      | Controls      | <i>p</i> -value | Patients              | Controls   |
| N                                | 250           | 218           |                 | 84 (33.6%)            | 3 (1.3%)   |
| Sex ratio (Men:Women)            | 1.2 (136:114) | 1.1 (112:106) | 0.51            | 1.1 (44:40)           | 2 (2:1)    |
| Mean age (years, SD)             | 65.8 (10.8)   | 62.2 (10.5)   | 0.34            | 64.1 (11.5)           | 55.3 (7.5) |
| Median age (years, IQR)          | 66 (59–75)    | 61.5 (53–71)  |                 | 64 (57–74)            | 55 (48–63) |
| Mean age at onset (years, SD)    | 58.5 (12.3)   | –             |                 | 56.1 (12.7)           | –          |
| Median age at onset (years, IQR) | 59 (49–67)    | –             |                 | 57 (46–65)            | –          |

**Table 2** Demographics of PD patients with and without LRRK2 G2019S mutations

|                                  | LRRK2 G2019S Carriers |              |              | LRRK2 G2019S Non-carriers | p-value |
|----------------------------------|-----------------------|--------------|--------------|---------------------------|---------|
|                                  | ALL                   | Homozygous   | Heterozygous |                           |         |
| N                                | 84                    | 8            | 76           | 166                       |         |
| Sex ratio (Men:Women)            | 1.1 (44:40)           | 1 (4:4)      | 1.1 (40:36)  | 1.2 (92:74)               | 0.68    |
| Mean age at onset (years, SD)    | 56.1 (12.7)           | 56 (7.8)     | 56.2 (13.2)  | 59.6 (12)                 | 0.44    |
| Median age at onset (years, IQR) | 57 (46–65)            | 57.5 (52–61) | 57 (46–65)   | 60.5 (51–69)              |         |

in accordance with previous Tunisian cohort studies [15, 16]. However, Ishihara et al. [13] reported that both homozygous and heterozygous G2019S individuals were older at onset than non-carrier patients. This difference could be explained by the familial nature of the study, including only related individuals (Table 3). In future studies, the screening strategy of the *LRRK2* G2019S mutation in the Tunisian population would focus on the recruitment of symptomatic individuals, regardless of age, gender or family history.

Through the development of whole genome sequencing by next-generation sequencing (NGS) technologies, a large number of polymorphic SNP linked to neurodegenerative disease were identified. The classic genotyping method using Sanger sequencing and PCR-RFLP were costly and labor-intensive. Thus, a high-throughput and cost effective platform was required to carry out large-scale genotyping of these SNPs of interest.

The KASP genotyping system has been used widely and successfully over many years in the field of genetic improvement of animals and field crops [8]. In our work, we screened the rs34637584 in 250 PD patients using KASP genotyping assay. Sixty samples out of 250 were then screened by Taqman and Sanger sequencing in order to assess the reliability and the cost of methods used.

Unlike Sanger sequencing, both KASP and Taqman assays possessed mutual advantages, like low-labor, cost and high-tolerance of variability in DNA quantity and quality. The assays could be conducted for large numbers of samples within a short period of time without post-PCR handling [8, 17]. These properties are critical for a large-scale genetic testing. Moreover, KASP and

Taqman genotyping PCR's are suitable for use on a variety of real-time PCR instruments. However, the main drawback for these assays is their limited capacity to be used for SNP multiplexing.

Furthermore, KASP had higher advantage than Taqman. It did not require labelling of the SNP-specific primers which reduced the cost. Thus, KASP genotyping offered by different laboratory worldwide showed a significant cost saving option compared to common Taqman technologies. According to previous studies and some commercial genotyping service providers, the current KASP reaction costs five times cheaper than Taqman. Moreover, a study of SNP selection for the soybean genotyping [17] has shown that allele-specific assay cost 0.005 US\$ for KASP compared to 0.238 US\$ for Taqman.

In addition, KASP allows a greater flexibility for primer design which increased overall success rate and offered an exceptionally accurate genotyping solution. Previous work has assessed the effectiveness of KASP genotyping technologies compared to Taqman or Sanger sequencing. According to an application note published by the University of Nottingham, the KASP technique was more efficient than TaqMan in terms of successful design of custom genotyping assays for a rare variant associated with Alzheimer's disease [18].

The *LRRK2* G2019S mutation was screened in populations worldwide using classical targeted sequencing, High-resolution melting analysis and TaqMan genotyping assay. Ours was the first study using KASP genotyping to screen this recurrent mutation. KASP was used to genotype other SNP's linked to PD, like the *LRRK2* variant rs1491942 and other SNPs in the *PARK16* locus in a Scandinavian population [19]. Besides, this technique

**Table 3** Summary of previous screening studies of the G2019S mutation in the Tunisian population

| Reference                 | Type of study      | Frequency in patients (%) | Frequency in controls (%) |
|---------------------------|--------------------|---------------------------|---------------------------|
| Ishihara et al. 2007 [13] | Familial           | 38/91 (42%)               | ND <sup>a</sup>           |
| Hulihan et al. 2008 [15]  | Unrelated patients | 72/238 (30%)              | 7/371(2%)                 |
| Trinh et al. 2014 [16]    | Unrelated patients | 220/570 (38%)             | 12/580 (3%)               |
|                           | Related patients   | 126/288 (45%)             |                           |
| The present study         | Unrelated patients | 84/250 (33.6%)            | 3/218 (1.3%)              |

<sup>a</sup>ND not defined

was used to screen for variants in regulatory regions of *SNCA* associated with PD [20]. It was often required to confirm the association of rare variants with a particular phenotype like the rare R1205H and D620N mutations of *4G1* and *VSP* gene, respectively, in South African PD patients [21]. Moreover, KASP genotyping assay was recently used to screen SNPs in different neurological disorder like Alzheimer's disease (rs75932628 of *TREM2* [22], rs1476679 of *ZCWPWI* gene [23] and both rs7412 and rs429358 for Apolipoprotein E genotyping [24]), amyotrophic lateral sclerosis [25], genetic generalized epilepsy (*VRK2* rs2947349 [26]) and polyglutamine diseases [27].

## Conclusions

By using KASP genotyping assay, we have shown that the G2019S mutation frequency in a PD Tunisian patient's cohort was similar to that reported in previous studies. The KASP technique could be a reliable genotyping assay for routine mutation screening in genetic testing. The implementation of this diagnostic activity within hospitals in Tunisia and in other North African or emerging countries will pave the way for personalized medicine in these countries and could improve the management of PD patients and their families.

## Abbreviations

HWE: Hardy-Weinberg equilibrium; KASP: Kompetitive Allele Specific PCR; LRRK2: Leucine-rich repeat kinase 2; PCR: Polymerase chain reaction; PD: Parkinson's disease; SNP: Single-nucleotide polymorphism; UKPDS: United Kingdom Parkinson's disease Society; WES: Whole exome sequencing

## Acknowledgments

We are grateful to all the patients and their family members for participating in this study.

## Funding

This research was supported by grants from the Tunisian Ministry of Higher Education and Scientific Research. Z.L has financial support within the framework of MOBIDOC Postdoc as specified in the PASRI program, funded by the European Union and managed by the ANPR.

## Availability of data and materials

Data supporting the findings are included in the article. Any further information is available on request to the corresponding author.

## Authors' contributions

RG is corresponding author and supervised the entire project. ZL, first author, conducted experiments and wrote the article, SB and HD assisted in the experiments. Study conception and design: ZL, RK, SA and CM. Patients follow-up: MB and AG-B. Data analysis and interpretation: ZL, MB, MD and SA. All authors have read and approved the final version of the manuscript.

## Ethics approval and consent to participate

Written informed consents were obtained from individuals before being enrolled in the genetic study. Research protocols were approved by the medical ethics committee of Razi Hospital and conformed to the guidelines of the Declaration of Helsinki.

## Consent for publication

All participants included in this study signed a written informed consent for publication.

## Competing interests

The authors declare that they have no competing interests.

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

## Author details

<sup>1</sup>Department of Neurology, UR12SP21, Razi Hospital, 1 rue des Orangers, 2010 Tunis, Manouba, Tunisia. <sup>2</sup>Laboratory of Biomedical Genomics and Oncogenetics, Institut Pasteur de Tunis, University of Tunis El Manar, BP 74, 13 Place Pasteur, 1002 Tunis, Tunisia. <sup>3</sup>Department of Neurology, Habib Bourguiba Hospital, 3029 Sfax, CP, Tunisia. <sup>4</sup>Faculty of Medicine of Tunis, University of Tunis El Manar, Tunis, Tunisia. <sup>5</sup>National Institute of Applied Science and Technology, University of Carthage, Tunis, Tunisia.

Received: 10 November 2016 Accepted: 19 June 2017

Published online: 06 July 2017

## References

- Paisan-Ruiz C, Jain S, Evans EW, Gilks WP, Simon J, van der Brug M, Lopez de Munain A, Aparicio S, Gil AM, Khan N, et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. *Neuron*. 2004;44(4):595–600.
- Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, Kachergus J, Hulihan M, Uitti RJ, Calne DB, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. *Neuron*. 2004;44(4):601–7.
- Cookson MR. Cellular effects of LRRK2 mutations. *Biochem Soc Trans*. 2012;40(5):1070–3.
- Rudenko IN, Cookson MR. Heterogeneity of leucine-rich repeat kinase 2 mutations: genetics, mechanisms and therapeutic implications. *Neurotherapeutics*. 2014;11(4):738–50.
- Mata IF, Wedemeyer WJ, Farrer MJ, Taylor JP, Gallo KA. LRRK2 in Parkinson's disease: protein domains and functional insights. *Trends Neurosci*. 2006;29(5):286–93.
- Correia Guedes L, Ferreira JJ, Rosa MM, Coelho M, Bonifati V, Sampaio C. Worldwide frequency of G2019S LRRK2 mutation in Parkinson's disease: a systematic review. *Parkinsonism Relat Disord*. 2010;16(4):237–42.
- Lesage S, Leutenegger AL, Ibanez P, Janin S, Lohmann E, Durr A, Brice A. LRRK2 haplotype analyses in European and North African families with Parkinson disease: a common founder for the G2019S mutation dating from the 13th century. *Am J Hum Genet*. 2005;77(2):330–2.
- He C, Holme J, Anthony J. SNP genotyping: the KASP assay. *Methods Mol Biology (Clifton, NJ)*. 2014;1145:75–86.
- Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. *Nucleic Acids Res*. 1988;16(3):1215.
- Change N, Mercier G, Lucotte G. Genetic screening of the G2019S mutation of the LRRK2 gene in Southwest European, North African, and Sephardic Jewish subjects. *Genet Test*. 2008;12(3):333–9.
- Tomiyama H, Li Y, Funayama M, Hasegawa K, Yoshino H, Kubo S, Sato K, Hattori T, Lu CS, Inzelberg R, et al. Clinicogenetic study of mutations in LRRK2 exon 41 in Parkinson's disease patients from 18 countries. *Mov Disord*. 2006;21(8):1102–8.
- Lesage S, Ibanez P, Lohmann E, Pollak P, Tison F, Tazir M, Leutenegger AL, Guimaraes J, Bonnet AM, Agid Y, et al. G2019S LRRK2 mutation in French and North African families with Parkinson's disease. *Ann Neurol*. 2005;58(5):784–7.
- Ishihara L, Gibson RA, Warren L, Amouri R, Lyons K, Wielinski C, Hunter C, Swartz JE, Elango R, Akkari PA, et al. Screening for Lrrk2 G2019S and clinical comparison of Tunisian and North American Caucasian Parkinson's disease families. *Mov Disord*. 2007;22(1):55–61.
- Warren L, Gibson R, Ishihara L, Elango R, Xue Z, Akkari A, Ragone L, Pahwa R, Jankovic J, Nance M, et al. A founding LRRK2 haplotype shared by Tunisian, US, European and Middle Eastern families with Parkinson's disease. *Parkinsonism Relat Disord*. 2008;14(1):77–80.
- Hulihan MM, Ishihara-Paul L, Kachergus J, Warren L, Amouri R, Elango R, Prinjha RK, Upmanyu R, Kefi M, Zouari M, et al. LRRK2 Gly2019Ser penetrance in Arab-Berber patients from Tunisia: a case-control genetic study. *Lancet Neurol*. 2008;7(7):591–4.

16. Trinh J, Amouri R, Duda JE, Morley JF, Read M, Donald A, Vilarino-Guell C, Thompson C, Szu Tu C, Gustavsson EK, et al. Comparative study of Parkinson's disease and leucine-rich repeat kinase 2 p.G2019S parkinsonism. *Neurobiol Aging*. 2014;35(5):1125–31.
17. Yuan J, Wen Z, Gu C, Wang D. Introduction of high throughput and cost effective SNP genotyping platforms in soybean. *Plant Genet Genomics Biotechnol*. 2014;1(3):90–4.
18. Braae A, Thompson C, Morgan K: Comparison of custom designed KASP and TaqMan genotyping assays for a rare genetic variant identified through resequencing GWAS loci. LGC, University of Nottingham - app note:2014. [https://www.lgcgroup.com/LGCGroup/media/PDFs/services/Genotyping/App%20notes\\_Case%20studies/Universitynottingham-app-note.pdf?ext=.pdf](https://www.lgcgroup.com/LGCGroup/media/PDFs/services/Genotyping/App%20notes_Case%20studies/Universitynottingham-app-note.pdf?ext=.pdf)
19. Pihlstrom L, Rengmark A, Bjornara KA, Dizdar N, Fardell C, Forsgren L, Holmberg B, Larsen JP, Linder J, Nissbrandt H, et al. Fine mapping and resequencing of the PARK16 locus in Parkinson's disease. *J Hum Genet*. 2015;60(7):357–62.
20. Schmitt I, Wullner U, van Rooyen JP, Khazneh H, Becker J, Volk A, Kubisch C, Becker T, Kostic VS, Klein C, et al. Variants in the 3'UTR of SNCA do not affect miRNA-433 binding and alpha-synuclein expression. *Eur J Hum Genet*. 2012;20(12):1265–9.
21. Blanckenberg J, Ntsapi C, Carr JA, Bardien S. EIF4G1 R1205H and VPS35 D620N mutations are rare in Parkinson's disease from South Africa. *Neurobiol Aging*. 2014;35(2):445.e441–3.
22. Benitez BA, Jin SC, Guerreiro R, Graham R, Lord J, Harold D, Sims R, Lambert JC, Gibbs JR, Bras J, et al. Missense variant in TREML2 protects against Alzheimer's disease. *Neurobiol Aging*. 2014;35(6):1510.e1519–26.
23. Allen M, Kachadoorian M, Carrasquillo MM, Karhade A, Manly L, Burgess JD, Wang C, Serie D, Wang X, Siuda J, et al. Late-onset Alzheimer disease risk variants mark brain regulatory loci. *Neurol Genet*. 2015;1(2):e15.
24. Keogh MJ, Wei W, Wilson I, Coxhead J, Ryan S, Rollinson S, Griffin H, Kurzawa-Akanbi M, Santibanez-Koref M, Talbot K, et al. Genetic compendium of 1511 human brains available through the UK Medical Research Council Brain Banks Network Resource. *Genome Res*. 2017;27(1):165–73.
25. Fogh I, Ratti A, Gellera C, Lin K, Tiloca C, Moskvina V, Corrado L, Soraru G, Cereda C, Corti S, et al. A genome-wide association meta-analysis identifies a novel locus at 17q11.2 associated with sporadic amyotrophic lateral sclerosis. *Hum Mol Genet*. 2014;23(8):2220–31.
26. Epilepsies ILAECoc. Genetic determinants of common epilepsies: a meta-analysis of genome-wide association studies. *Lancet Neurol*. 2014;13(9):893–903.
27. Bettencourt C, Hensman-Moss D, Flower M, Wiethoff S, Brice A, Goizet C, Stevanin G, Koutsis G, Karadima G, Panas M, et al. DNA repair pathways underlie a common genetic mechanism modulating onset in polyglutamine diseases. *Ann Neurol*. 2016;79(6):983–90.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)

